<ul>
<li>辉瑞与特朗普政府的定价协议推动了股价上涨。</li>
<li>华尔街的看涨者仍然认为未来还有更多上涨空间，因为这家跌落的制药公司希望重新夺回自 COVID 高峰以来失去的市场份额。</li>
<li>你在退休方面是领先还是落后？SmartAsset 的免费工具可以在几分钟内将你与财务顾问匹配，帮助你今天回答这个问题。每位顾问都经过严格审查，必须以你的最佳利益为重。不要再浪费时间；在这里了解更多。(赞助商)</li>
</ul>
<p><strong>辉瑞</strong> (NYSE:PFE) 的股票在与特朗普政府达成定价协议的消息传出后，终于开始吸引关注，在单个交易日内上涨近 7%。实际上，这是辉瑞股票近期最大的单日涨幅。尽管投资者对定价计划持乐观态度，但我认为收入投资者应该关注眼前的长期机会。</p>
<p>确实，近期这家陷入困境的制药公司股票的最新上涨使得股息收益率在过去一周内压缩了近 0.5%。在突然激增之后，辉瑞股票的股息收益率为 6.75%，虽然较小，但仍然具有吸引力，并且得到了良好的覆盖。</p>
<h2>TrumpRX 为辉瑞股票带来了变化。其他制药公司是否会有更多类似的交易？</h2>
<p>无论如何，我认为辉瑞股票的最新飙升只是回归更高水平的持续上涨的开始，尤其是 “TrumpRX” 希望在辉瑞过去一年大部分时间陷入低谷后给予其急需的提振。辉瑞准备通过医疗补助削减处方药价格，这家价值 1450 亿美元的制药巨头可能会遭受一定的利润打击。然而，在接下来的三年里，它将享受显著的关税减免。确实，一些药物的价格将减少 85%，这相当可观。</p>
<p>表面上看，这似乎是一个双赢的交易，但我认为其他制药公司将会效仿辉瑞，可能会达成类似的交易。因此，我认为辉瑞股票的最新反弹很可能是短暂的。无论如何，投资者可能希望在股价接近每股 24 美元时入场，因为更多分析师将有机会对这一可能对整个行业产生深远影响的交易发表看法。</p>
<p>或许重新审视辉瑞股票的最大理由是其极低的估值。在撰写本文时，辉瑞股票的市盈率为 13.4 倍，或约为前瞻市盈率的八倍。这是非常便宜的。考虑到市场上较高的股息收益率，收入投资者可能会被吸引，考虑在 TrumpRX 交易的背景下投资这只深度价值的制药股。</p>
<h2>一些非常显著的华尔街看涨者认为辉瑞股票将从这里获得更多上涨空间</h2>
<p>辉瑞股票最大的看涨者必须是杰富瑞分析师 Akash Tewari，他对辉瑞的每股目标价保持在 34 美元。尽管在 TrumpRX 交易后他的看法会很有趣，但我不禁想他会变得更加乐观。作为他当前理论的一部分，他认为辉瑞正在节省大量成本，因为其运营效率的努力开始见效。此外，投资于美国制造业也是一个利好，因为该公司避免了关税。</p>
<p>即使在周二的突然反弹之后，辉瑞股票仍然有大约 33% 的上涨空间，这还不包括近 7% 的股息收益率。无论如何，我会期待更多华尔街分析师在今年最大的行业交易之一之后，发表对这家跌落的制药蓝筹股的更乐观看法。</p>
<p>虽然 TrumpRX 交易是一个重大利好，但它并不会神奇地解决辉瑞的所有问题。该公司一直在通过收购实现更大的增长，最近近 50 亿美元的交易使其进入了减肥药市场，而该市场在今年大幅降温。辉瑞是否为进入制药行业的热门领域支付了过高的价格仍然是一个大问题。无论如何，投资者在追逐高收益价值股时应注意风险，尤其是在它们刚刚从低谷中走出时。</p>
<p>本文的标题为《这只 6.75% 收益的股息股票可以上涨 33%》，首次发表于 24/7 Wall St..</p>

辉瑞

<p>辉瑞（NYSE:PFE）股票在与特朗普政府达成定价协议后上涨近 7%，标志着该股票的一个显著上涨日。分析师预测，从当前水平来看，潜在的上涨空间可达 33%，并且支持这一预测的是 6.75% 的股息收益率。尽管有积极的势头，但人们对这一反弹的可持续性以及公司近期的收购仍然存在担忧。该协议可能导致处方药价格下降，影响利润率，但同时提供关税减免。投资者在评估辉瑞的长期前景时，建议考虑与高收益股票相关的风险</p>

<ul>
<li>Pfizer’s pricing deal with the Trump administration has been powering shares higher.</li>
<li>Wall Street bulls still see more upside ahead as the fallen pharma firm looks to gain ground it had lost since its COVID peak.</li>
<li>Are you ahead, or behind on retirement? SmartAsset’s free tool can match you with a financial advisor in minutes to help you answer that today. Each advisor has been carefully vetted, and must act in your best interests. Don’t waste another minute; learn more here.(Sponsor)</li>
</ul>
<div class="lb-trans"><ul>
<li>辉瑞与特朗普政府的定价协议推动了股价上涨。</li>
<li>华尔街的看涨者仍然认为未来还有更多上涨空间，因为这家跌落的制药公司希望重新夺回自 COVID 高峰以来失去的市场份额。</li>
<li>你在退休方面是领先还是落后？SmartAsset 的免费工具可以在几分钟内将你与财务顾问匹配，帮助你今天回答这个问题。每位顾问都经过严格审查，必须以你的最佳利益为重。不要再浪费时间；在这里了解更多。(赞助商)</li>
</ul>
</div><p><strong>Pfizer</strong> (NYSE:PFE) shares are finally starting to attract attention after gaining close to 7% in a single trading session on news that it’s reached a pricing deal with the Trump administration. Indeed, this is the biggest up day for shares of PFE in recent memory. And while investors are upbeat on the pricing plan, I do think that income investors should focus on the longer-term opportunity at hand.</p>
<div class="lb-trans"><p><strong>辉瑞</strong> (NYSE:PFE) 的股票在与特朗普政府达成定价协议的消息传出后，终于开始吸引关注，在单个交易日内上涨近 7%。实际上，这是辉瑞股票近期最大的单日涨幅。尽管投资者对定价计划持乐观态度，但我认为收入投资者应该关注眼前的长期机会。</p>
</div><p>Indeed, the latest upswing in the ailing pharmaceutical stock has compressed the dividend yield by close to 0.5% in the past week. After the sudden surge, PFE stock boasts a smaller, but still attractive 6.75% dividend yield, and it’s a well-covered one.</p>
<div class="lb-trans"><p>确实，近期这家陷入困境的制药公司股票的最新上涨使得股息收益率在过去一周内压缩了近 0.5%。在突然激增之后，辉瑞股票的股息收益率为 6.75%，虽然较小，但仍然具有吸引力，并且得到了良好的覆盖。</p>
</div><h2>TrumpRX has moved the needle for PFE stock. Could more similar deals be on the horizon for other drugmakers?</h2>
<div class="lb-trans"><h2>TrumpRX 为辉瑞股票带来了变化。其他制药公司是否会有更多类似的交易？</h2>
</div><p>In any case, I think the latest spike in PFE stock is just the start of a sustained run back to higher levels, especially as “TrumpRX” looks to give Pfizer a much-needed boost after spending most of the last year falling further into the abyss. With Pfizer poised to slash prices on prescription drugs via Medicaid, the $145 billion pharma giant might take a bit of a margin hit. However, it’ll enjoy significant relief on tariffs over the next three years. Indeed, some drugs will see an 85% reduction in price, which is pretty massive.</p>
<div class="lb-trans"><p>无论如何，我认为辉瑞股票的最新飙升只是回归更高水平的持续上涨的开始，尤其是 “TrumpRX” 希望在辉瑞过去一年大部分时间陷入低谷后给予其急需的提振。辉瑞准备通过医疗补助削减处方药价格，这家价值 1450 亿美元的制药巨头可能会遭受一定的利润打击。然而，在接下来的三年里，它将享受显著的关税减免。确实，一些药物的价格将减少 85%，这相当可观。</p>
</div><p>On the surface, it looks like a win-win deal, but I do think that other pharma firms will follow in the footsteps of Pfizer, likely to land similar deals of their own. As such, I think the latest bounce in PFE stock has a good chance of being short-lived. Either way, investors may wish to punch their ticket on a fall closer to the $24 per-share range, as more analysts have the opportunity to chime in on a deal that could have sweeping industry-wide implications.</p>
<div class="lb-trans"><p>表面上看，这似乎是一个双赢的交易，但我认为其他制药公司将会效仿辉瑞，可能会达成类似的交易。因此，我认为辉瑞股票的最新反弹很可能是短暂的。无论如何，投资者可能希望在股价接近每股 24 美元时入场，因为更多分析师将有机会对这一可能对整个行业产生深远影响的交易发表看法。</p>
</div><p>Perhaps the biggest reason to give PFE shares a second look is the rock-bottom valuation to be had. At the time of this writing, shares trade at 13.4 times trailing price-to-earnings (P/E) or around eight times forward P/E. That’s incredibly cheap. And with one of the more swollen dividend yields on the market, income investors might be tempted to board the deep-value pharma play in light of the TrumpRX deal.</p>
<div class="lb-trans"><p>或许重新审视辉瑞股票的最大理由是其极低的估值。在撰写本文时，辉瑞股票的市盈率为 13.4 倍，或约为前瞻市盈率的八倍。这是非常便宜的。考虑到市场上较高的股息收益率，收入投资者可能会被吸引，考虑在 TrumpRX 交易的背景下投资这只深度价值的制药股。</p>
</div><h2>Some very notable Wall Street bulls see shares of PFE gaining more ground from here</h2>
<div class="lb-trans"><h2>一些非常显著的华尔街看涨者认为辉瑞股票将从这里获得更多上涨空间</h2>
</div><p>The biggest bull on Pfier stock has to be Jefferies analyst Akash Tewari, who holds onto a $34 per-share price target. Though it’ll be interesting to get his take following the TrumpRX deal, I can’t help but think he’ll grow even more upbeat. As a part of his current thesis, he thinks Pfizer is on track to save a great deal as its operational efficiency efforts look to pay off. Additionally, investments in U.S. manufacturing are a plus as the firm steers clear of tariffs.</p>
<div class="lb-trans"><p>辉瑞股票最大的看涨者必须是杰富瑞分析师 Akash Tewari，他对辉瑞的每股目标价保持在 34 美元。尽管在 TrumpRX 交易后他的看法会很有趣，但我不禁想他会变得更加乐观。作为他当前理论的一部分，他认为辉瑞正在节省大量成本，因为其运营效率的努力开始见效。此外，投资于美国制造业也是一个利好，因为该公司避免了关税。</p>
</div><p>Even after Tuesday’s sudden rally, PFE stock still has another 33% or so in upside from current levels, and that’s not including the near-7% dividend yield. Either way, I’d look for more Wall Street analysts to step forward with more upbeat views of the fallen pharma blue-chip following one of the biggest deals for the industry all year.</p>
<div class="lb-trans"><p>即使在周二的突然反弹之后，辉瑞股票仍然有大约 33% 的上涨空间，这还不包括近 7% 的股息收益率。无论如何，我会期待更多华尔街分析师在今年最大的行业交易之一之后，发表对这家跌落的制药蓝筹股的更乐观看法。</p>
</div><p>While the TrumpRX deal is a major positive, it won’t magically solve all of Pfizer’s issues. The firm has been acquiring its way to greater growth, with the most recent near-$5 billion deal punching the firm’s ticket to the weight-loss drug race, which has cooled off in a big way this year. As to whether Pfizer is overpaying for entry into hot corners of pharma remains the big question. In any case, investors should be mindful of the risks in chasing high-yield value plays, especially as they get off the canvas.</p>
<div class="lb-trans"><p>虽然 TrumpRX 交易是一个重大利好，但它并不会神奇地解决辉瑞的所有问题。该公司一直在通过收购实现更大的增长，最近近 50 亿美元的交易使其进入了减肥药市场，而该市场在今年大幅降温。辉瑞是否为进入制药行业的热门领域支付了过高的价格仍然是一个大问题。无论如何，投资者在追逐高收益价值股时应注意风险，尤其是在它们刚刚从低谷中走出时。</p>
</div><p>The post This 6.75%-Yielding Dividend Stock Can Gain 33% appeared first on 24/7 Wall St..</p>
<div class="lb-trans"><p>本文的标题为《这只 6.75% 收益的股息股票可以上涨 33%》，首次发表于 24/7 Wall St..</p>
</div>

This 6.75%-Yielding Dividend Stock Can Gain 33%

- 辉瑞与特朗普政府达成定价协议，股价上涨近 7%。  
- 分析师认为辉瑞股价还有 33% 的上涨空间，尽管面临风险。  
- 辉瑞的股息收益率为 6.75%，吸引收入投资者关注。  

这只股息收益率为 6.75% 的股票有望上涨 33%